Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect

References

• Abe K, Bridges AS, Brouwer KL. (2009). Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37:447–452.
   PubMed Web of Science ®Google Scholar
• Bi YA, Kazolias D, Duignan DB. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658–1665.
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF, Annaert PP. (2011). Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci 43:297–307.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (2012). Guideline on the Investigation of Drug Interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B. (2008). Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57–65.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos 34:1829–1836.
   PubMed Web of Science ®Google Scholar
• Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD. (2010). Transporter studies with the 3-O-sulfate conjugate of 17α-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 38:1072–1082.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–1236.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–522.
   PubMed Web of Science ®Google Scholar
• Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, Tanaka M. (1992a). Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17:103–113.
   PubMed Web of Science ®Google Scholar
• Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, Horiuchi S. (1992b). Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667–670.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugiyama Y. (2010). The use of hepatocytes to investigate drug uptake transporters. Methods Mol Biol 640:327–353.
   PubMedGoogle Scholar
• Menochet K, Kenworthy KE, Houston JB, Galetin A. (2012). Use of Mechanistic Modelling to Assess Inter-Individual Variability and Inter-species Differences in Active Uptake in Human and Rat Hepatocytes. Drug Metab Dispos. DOI:10.1124/dmd.112.046193.
   Google Scholar
• Morrison RA, Singhvi MS. (1996). Pharmacokinetics and oral bioavailability of pravastatin in dogs. Int J Pharm 143:265–269.
   Google Scholar
• Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K. (2001). Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861–867.
   PubMed Web of Science ®Google Scholar
• Poirier A, Lavé T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C. (2008). Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos 36:2434–2444.
   PubMed Web of Science ®Google Scholar
• Romaine SP, Bailey KM, Hall AS, Balmforth AJ. (2010). The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10:1–11.
   PubMed Web of Science ®Google Scholar
• Singhvi SM, Pan HY, Morrison RA, Willard DA. (1990). Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29:239–243.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK.. (2006). Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro 20:1582–1586.
   PubMed Web of Science ®Google Scholar
• Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–865.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Service, Food and Drug Administration (2012). Guidance for Industry: Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
   Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. (2010). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–222.
   PubMed Web of Science ®Google Scholar
• Webborn PJ, Parker AJ, Denton RL, Riley RJ. (2007). In vitro-in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. Xenobiotica 37:1090–1109.
   PubMed Web of Science ®Google Scholar
• Yabe Y, Galetin A, Houston JB. (2011). Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808–1814.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. (1996). Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 13:1559–1564.
   PubMed Web of Science ®Google Scholar